| scholarly article | Q13442814 |
| P50 | author | Manfred S. Green | Q60299906 |
| P2093 | author name string | D. Cohen | |
| I. Ofek | |||
| C. Block | |||
| R. Slepon | |||
| P2860 | cites work | Microtiter bacterial hemagglutination technique for detection of Shigella antibodies | Q35175362 |
| Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp. | Q37027574 | ||
| Cytotoxicity of human peripheral blood and colostral leukocytes against Shigella species | Q37037721 | ||
| Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections | Q37167794 | ||
| Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease | Q37208278 | ||
| Protection of Monkeys Against Experimental Shigellosis with a Living Attenuated Oral Polyvalent Dysentery Vaccine | Q37387409 | ||
| Shigella sonnei phase I and phase II: susceptibility to direct serum lysis and opsonic requirements necessary for stimulation of leukocyte redox metabolism and killing | Q40610910 | ||
| Protection against keratoconjunctivitis shigellosa induced by immunization with outer membrane proteins of Shigella spp. | Q41186719 | ||
| Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial | Q42982958 | ||
| Failure of parenteral vaccines to protect monkeys against experimental shigellosis | Q47710064 | ||
| Serum factors responsible for killing of Shigella | Q47847980 | ||
| Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine | Q50201269 | ||
| The antibody response to bacterial gastroenteritis in serum and secretions. | Q50218681 | ||
| Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens. | Q52223098 | ||
| Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella | Q67235888 | ||
| Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population | Q68134308 | ||
| Natural cytotoxic effector cell activity against Shigella flexneri-infected HeLa cells | Q68857501 | ||
| Local and systemic antibody responses to Shigella infection in rhesus monkeys | Q68944588 | ||
| Immunity in Shigellosis. II. Protection Induced by Oral Live Vaccine or Primary Infection | Q69156182 | ||
| Shigellosis in custodial institutions | Q71541469 | ||
| Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment | Q78615786 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| lipopolysaccharide | Q421804 | ||
| P304 | page(s) | 386-389 | |
| P577 | publication date | 1991-02-01 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis | |
| P478 | volume | 29 |
| Q49210830 | A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country |
| Q64948328 | Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. |
| Q33498177 | Alterations in lymphocyte phenotype and function in children with shigellosis who develop complications. |
| Q40126474 | An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype. |
| Q37668395 | An update on vaccines against Shigella |
| Q35805439 | Broadly protective Shigella vaccine based on type III secretion apparatus proteins |
| Q38776163 | Characterization of a multicomponent live, attenuated Shigella flexneri vaccine |
| Q36105069 | Characterization of the rfc region of Shigella flexneri |
| Q92487093 | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q35771562 | Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid |
| Q38683902 | Correlates of protection for enteric vaccines |
| Q35227169 | Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination |
| Q54572055 | Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. |
| Q37458618 | Effect of wild-type Shigella species and attenuated Shigella vaccine candidates on small intestinal barrier function, antigen trafficking, and cytokine release |
| Q37066116 | Establishment of a Shigella sonnei human challenge model in Thailand |
| Q37032264 | Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. |
| Q50104933 | Histopathological study of rabbit intestinal mucosa infected with a hybrid strain of Shigella dysenteriae 1 carrying LPS biosynthesis genes of Salmonella enterica serovar typhimurium |
| Q39230762 | How Do the Virulence Factors of Shigella Work Together to Cause Disease? |
| Q99616552 | Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G |
| Q35521181 | Immune response to Shigella sonnei in U.S. Marines |
| Q40460000 | Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. |
| Q39822100 | Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis |
| Q28972559 | Immunology of Gut Mucosal Vaccines |
| Q38648043 | In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity. |
| Q35621105 | Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study |
| Q39822312 | Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection |
| Q33497678 | Lipopolysaccharide-specific antibodies in plasma and stools of children with Shigella-associated leukemoid reaction and hemolytic-uremic syndrome |
| Q57922815 | Microevolution and Patterns of Transmission of Shigella sonnei within Cyclic Outbreaks Shigellosis, Israel |
| Q36365336 | Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis |
| Q43623067 | Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice |
| Q35844488 | O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative |
| Q34006071 | Parameters underlying successful protection with live attenuated mutants in experimental shigellosis |
| Q36989971 | Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. |
| Q35924773 | Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB |
| Q37105553 | Progress and pitfalls in Shigella vaccine research |
| Q78171100 | Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines |
| Q42227472 | Recent trends in the epidemiology of shigellosis in Israel |
| Q35443019 | Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a. |
| Q92968346 | Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development |
| Q38665950 | Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. |
| Q59809065 | Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: Results of a Phase 2, randomized, double-blind placebo-controlled trial |
| Q34008338 | Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults |
| Q102056730 | Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study |
| Q40501431 | Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial |
| Q34006223 | Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel |
| Q35523144 | Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers |
| Q36945836 | Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. |
| Q35528270 | Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. |
| Q91881906 | Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis |
| Q35225017 | Serum antibody to lipopolysaccharide antigens of Shigella species among U.S. military personnel deployed to Saudi Arabia and Kuwait during Operations Desert Shield and Desert Storm. |
| Q35946462 | Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice. |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q36920244 | Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. |
| Q34003433 | Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans |
| Q34202171 | Shigella isolates from the global enteric multicenter study inform vaccine development |
| Q56383780 | Shigellosis |
| Q36989057 | Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q38648228 | Summary of workshop "global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques". |
| Q33607442 | Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid |
| Q30597282 | The extant World War 1 dysentery bacillus NCTC1: a genomic analysis |
| Q36547740 | The transfer and decay of maternal antibody against Shigella sonnei in a longitudinal cohort of Vietnamese infants |
| Q34002272 | Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice |
| Q40098097 | Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice |
| Q91767150 | Vaccines for enteric diseases |
| Q41263122 | Whole genome analysis to detect potential vaccine-induced changes on Shigella sonnei genome. |
Search more.